These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1973560)

  • 1. Vascular and cardiac electrophysiological activity of GYKI-12 743 in isolated tissue preparations.
    Jednákovits A; Kovács A; Bódi I; Jaszlits L; Rabloczky G
    Acta Physiol Hung; 1990; 75 Suppl():157-8. PubMed ID: 1973560
    [No Abstract]   [Full Text] [Related]  

  • 2. Study of the predominant vascular postsynaptic alpha-adrenergic blocking capacity of GYKI-12 743 in isolated organs and pithed rats.
    Horváth E; Bódi I; Jaszlits L; Rabloczky G
    Acta Physiol Hung; 1990; 75 Suppl():145-6. PubMed ID: 1973558
    [No Abstract]   [Full Text] [Related]  

  • 3. GYKI-12 743, a novel antihypertensive compound with special alpha-adrenergic blocking profile.
    Jaszlits L; Rabloczky G; Csókás G; Bódi I; Kürthy M; Horváth E; Kovács A; Jednákovits A; Arányi P; Mátyus P
    Acta Physiol Hung; 1990; 75 Suppl():155-6. PubMed ID: 1973559
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical effects of GYKI-12 743.
    Bakonyi A; Tömösközi Z; Heiczman A; Horváth EJ; Arányi P; Rabloczky G
    Acta Physiol Hung; 1990; 75 Suppl():19-20. PubMed ID: 2164749
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (II).
    Khouili M; Guillaumet G; Coudert G; Pujol MD
    Farmaco; 1996 Mar; 51(3):185-8. PubMed ID: 8688140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (I).
    Khouili M; Guillaumet G; Coudert G; Pujol MD
    Farmaco; 1996 Mar; 51(3):175-84. PubMed ID: 8688139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of rausedyl and pyrroxan on autoregulation of cerebral circulation].
    Gaevyĭ MD; Pogorelyĭ VE
    Biull Eksp Biol Med; 1983 Jul; 96(7):56-9. PubMed ID: 6135465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-blocking properties of idazoxan (170150 or RX 781094) and its stereoisomers: applications to bronchomotricity.
    Floch A; Advenier C
    J Pharmacol; 1985; 16(3):291-7. PubMed ID: 2866275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alpha-adrenoblocking activity of a newly synthesized derivative of 1,4-benzodioxane].
    Staneva D; Spasov V; Ivanov D
    Eksp Med Morfol; 1984; 23(2):87-91. PubMed ID: 6147242
    [No Abstract]   [Full Text] [Related]  

  • 10. [Psychophysiologic aspect of regulating dyadic interpersonal interaction].
    Medvedev VI; Zav'ialova EK; Ovchinnikov BV; Posokhova ST
    Fiziol Cheloveka; 1986; 12(5):754-60. PubMed ID: 2880779
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of alpha-1 adrenergic receptors in the heart using [3H]WB4101: effect of 6-hydroxydopamine treatment.
    Yamada S; Yamamura HI; Roeske WR
    J Pharmacol Exp Ther; 1980 Oct; 215(1):176-85. PubMed ID: 6109014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardioprotective, vasorelaxant and electrophysiological profile of the large conductance calcium-activated potassium channel opener NS-004.
    Sargent CA; Grover GJ; Antonaccio MJ; McCullough JR
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1422-9. PubMed ID: 8371147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of the potassium channel opening activity of GYKI-12743 by 86Rb+ efflux studies.
    Bakonyi A; Horváth EJ
    Acta Physiol Hung; 1994; 82(4):295-300. PubMed ID: 7785439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of amezinium, a novel antihypotensive drug. II. Examination of cardiovascular effects.
    Lehmann HD; Giertz H; Kretzschmar R; Lenke D; von Philipsborn G; Raschack M; Schuster J
    Arzneimittelforschung; 1981; 31(9a):1544-57. PubMed ID: 7197969
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and pharmacological evaluation of some WB4101 analogues bearing a naphthodioxanic nucleus.
    Castagnino E; Strappaghetti G; Corsano S; Gallucci P; Brasili L; Giardinà D
    Farmaco Sci; 1984 Jul; 39(7):569-74. PubMed ID: 6148262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Action of idazoxan on tachycardia following electric stimulation of the thoracic sympathetic chain in the rat].
    Dabiré H; Fournier B; Schmitt H
    C R Seances Soc Biol Fil; 1986; 180(2):170-3. PubMed ID: 2877721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor interaction for the alpha-antagonist WB4101 (2(N[2,6-dimethyoxyphenoxyethyl])amino-methyl-1,4-benzodioxane).
    Kapur H; Mottram DR; Green PN
    J Pharm Pharmacol; 1978 Apr; 30(4):259-60. PubMed ID: 24721
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lactogenic effect of pyrroxan, a Soviet alpha-adrenoblockader].
    Kolodina LN; Poskalenko AN; Korkhov VV; Barannikova TA
    Akush Ginekol (Mosk); 1976 Aug; (8):60-2. PubMed ID: 11702
    [No Abstract]   [Full Text] [Related]  

  • 19. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idazoxan and blood gas changes.
    Raptopoulos D; Koutinas A; Moustardas N; Papasteriadis A
    Vet Rec; 1988 Jan; 122(2):47. PubMed ID: 2896410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.